Targeted Approaches for Addressing Taxane-Induced Neuropathic Pain in Breast Cancer Survivors: An In-Depth Review
Clinical Scorecard: Targeted Approaches for Addressing Taxane-Induced Neuropathic Pain in Breast Cancer Survivors: An In-Depth Review
At a Glance
| Category | Detail |
|---|
| Condition | Taxane-Induced Neuropathic Pain (TINP) |
| Key Mechanisms | Mitochondrial dysfunction, oxidative stress, axonal degeneration, maladaptive neuroplasticity, neuroimmune activation. |
| Target Population | Breast cancer survivors experiencing neuropathic pain due to taxane chemotherapy. |
| Care Setting | Oncology and pain management clinics. |
Key Highlights
- High incidence of TINP among breast cancer survivors, with 97% experiencing neuropathy after paclitaxel.
- Symptoms often include sensory, motor, or autonomic deficiencies, primarily in a 'stocking-and-glove' distribution.
- Various interventions including pharmacological treatments, neuromodulation, and manual therapies show promise.
- Need for more rigorous studies to evaluate the effectiveness of interventions targeting TINP.
Guideline-Based Recommendations
Diagnosis
- Assess symptoms of neuropathy in breast cancer survivors post-taxane treatment.
Management
- Consider pharmacological and non-pharmacological interventions tailored to individual patient needs.
Monitoring & Follow-up
- Regularly evaluate pain levels and functional status in patients undergoing treatment for TINP.
Risks
- Potential for dose reductions or treatment delays due to severe neuropathic pain.
Patient & Prescribing Data
Breast cancer survivors treated with taxanes.
Combination of pharmacological and non-pharmacological strategies may enhance pain management.
Clinical Best Practices
- Implement a multidisciplinary approach to manage TINP.
- Educate patients about potential side effects of taxane chemotherapy.
- Encourage physical activity and manual therapies as adjunctive treatments.
References
